Dr. William R. F. Goundry, AstraZeneca - Qepler Summits And Conferences

Dr. William R. F. Goundry

Associate Principal Scientist
Heaton Moor, United Kingdom
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

Following his D.Phil in organic synthesis at Oxford University and Post Doc at Indiana University Will joined AZ at Macclesfield in 2006.

He has developed a strong track record in process design and scale up working from grams to tonnes, including biocatalysis and flow chemistry.

For the last three years he has been working in the area of New Modalities with a recent secondment in the Advanced Drug Delivery team, designing and synthesising new materials for the intracellular delivery of mRNA.

Will is currently working on AstraZeneca’s antibody drug conjugate (ADC) platform, with accountability for early phase payload synthesis. In this role he is developing the commercial routes and processes for ADC payloads, whilst supporting the manufacture of clinical trial material.

He is an Honorary Lecturer at the University of Manchester in the Division of Pharmacy presently supporting a curriculum review.

Related Sessions:

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 19 Feb 2020
  • Prague, CZ
  • Pharma
Day 2: Thursday, 20 February 2020
CASE STUDY: Strategies for Successfully Scaling-up ADC Payloads
  • Challenges in scaling up ADC payloads
  • Strategies to scale-up ADC payloads including route design
  • Case Study one: Scaling up a Tubulysin payload
  • Case Study two: Scaling up a Pyrrolobenzodiazpene
View Details